Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Cidara Thera (CDTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 116,041
  • Shares Outstanding, K 21,390
  • Annual Sales, $ 0 K
  • Annual Income, $ -55,730 K
  • 36-Month Beta 2.05
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.28

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.85 +54.55%
on 05/11/18
6.05 -1.65%
on 05/25/18
+1.80 (+43.37%)
since 04/25/18
3-Month
3.70 +60.81%
on 04/16/18
8.55 -30.41%
on 03/15/18
-0.60 (-9.16%)
since 02/23/18
52-Week
3.70 +60.81%
on 04/16/18
8.80 -32.39%
on 10/25/17
-0.75 (-11.19%)
since 05/25/17

Most Recent Stories

More News
Cidara Therapeutics Announces Offering of Common Stock and Warrants

Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it has entered into a securities purchase agreement with...

CDTX : 5.95 (+9.68%)
Cidara Provides Corporate Update and Reports First Quarter 2018 Financial Results

Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months ended March 31, 2018 and...

CDTX : 5.95 (+9.68%)
Cidara Therapeutics to Present Rezafungin Data at the European Congress of Clinical Microbiology and Infectious Diseases 2018 Meeting

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data from preclinical studies of its lead...

CDTX : 5.95 (+9.68%)
Cidara Therapeutics Provides Clinical Data Updates for its Lead Antifungal Rezafungin

Additional data and analyses from STRIVE Phase 2 clinical trial confirm positive efficacy results in both rezafungin arms

CDTX : 5.95 (+9.68%)
Blog Exposure - Cidara Therapeutics Released Positive Top-line Results from Phase-2 STRIVE Trial Assessing its Lead Antifungal Rezafungin

Stock Monitor: BioTime Post Earnings Reporting

CDTX : 5.95 (+9.68%)
Options Traders Expect Huge Moves in Cidara Therapeutics (CDTX) Stock

Surging implied volatility makes Cidara Therapeutics (CDTX) stock lucrative to the option traders.

CDTX : 5.95 (+9.68%)
Cidara Therapeutics Reports Positive Topline Results from Phase 2 STRIVE Trial of Lead Antifungal Rezafungin

Favorable safety, tolerability, and efficacy observed in novel once-weekly echinocandin for difficult-to-treat invasive fungal infections

CDTX : 5.95 (+9.68%)
Shares of Progenics Pharm Rank the Highest in Terms of Relative Performance in the Biotechnology Industry (PGNX , TTOO, CDTX, TGTX , ADRO )

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

PGNX : 7.52 (+0.13%)
TTOO : 8.87 (+2.07%)
CDTX : 5.95 (+9.68%)
Cidara Therapeutics to Present Rezafungin Data at the European Society for Blood and Marrow Transplantation 2018 Meeting

Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that two rezafungin abstracts have been accepted for presentation...

CDTX : 5.95 (+9.68%)
Cidara Provides Corporate Update and Reports Fourth Quarter and Full Year 2017 Financial Results

Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months and full year ended December...

CDTX : 5.95 (+9.68%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade CDTX with:

Business Summary

Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical and C001 which are in different clinical trial. The company...

See More

Key Turning Points

2nd Resistance Point 6.38
1st Resistance Point 6.17
Last Price 5.95
1st Support Level 5.62
2nd Support Level 5.28

See More

52-Week High 8.80
Fibonacci 61.8% 6.85
Fibonacci 50% 6.25
Last Price 5.95
Fibonacci 38.2% 5.65
52-Week Low 3.70

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar